In this Issue:
Infused total nucleated cell dose as predictor of SCT outcomes
Prognostic value of Ki-67, cytology and growth pattern in mantle-cell lymphoma
RB/RC in transplant-eligible mantlecell lymphoma
IGHV gene identities and CLL outcomes
Impact of low-level BCR-ABL1 mutations on ponatinib response
Extended oral azacitidine dosing in lower-risk myelodysplastic syndrome
Age-related mutations and CMML
Interim PET response-adapted therapy in advanced HL
ABVD vs. BEACOPP vs. COPP-EBVCAD in HL: 10-year results
Please login below to download this issue (PDF)